Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Jul 22, 2015 1:48pm
51 Views
Post# 23949486

RE:RE:RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...

RE:RE:RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...gv, RVX had eliminated lipitor-208 from the initial P3 (pivotal) trial i presume they had did all the legwork to elminate lipitor-208 (relisten to some of the statements made and how sure they were and what they learned and blah, blah, blah)...they know lipitor-208 failed in ASSURE and had all data related to that to decide whether to include in a P3 and decided against it and now flip-flopped and are now including...IMO this is a PII (like ASSURE) but RVX is hoping with enough patients to pass the data tests for registration..ps re mono i thought 208 had positive clinical impact on its own but a combo with statins would prove synergistic (effect timeline would be shortened as wasn't that their claim in one of the failed trials it just took 208 too long (maybe needed 26 weeks)...ps on a different note i made a post on BTI MB and it speaks to a real problem on these MB, pikupstix made a fundamentally WABS claim (and as he is a professional i felt compelled to correct and shame him)  good news for BTI but not "earth shattering" as he was trying to pump...ps public flip-flops imo are incompetence i want to hear specifically why lipitor-208 now included..same as ODD pump job they know how long it takes
Bullboard Posts